NEW YORK – Immune mapping firm Serimmune has put the bulk of its previous research efforts on hold and shifted focus to aiding development of tests and vaccines for SARS-CoV-2.
The Goleta, California-based company combines next-generation sequencing with massive random peptide libraries to profile patient immune responses as part of research into diagnostic and therapeutic development for a variety of conditions including autoimmune diseases, cancers, and infectious disease.